Skip to content
Screener

Debt-to-equity at other companies

Semtech logo
SemtechSMTC
0.9×-0.1×
Synopsys logo
SynopsysSNPS
0.4×-0.7×
Nucor logo
NucorNUE
0.0×
Northern Trust logo
Northern TrustNTRS
0.0×
Dycom Industries logo
Dycom IndustriesDY
1.6×+0.7×
Nordson logo
NordsonNDSN
0.6×-0.2×

Other financials

Income statement

See full
Operating income-$26.1M-62.4%
Net income-$24.2M-97.8%
EPS (diluted)-$0.80+93.8%

Balance sheet

See full
Cash & equivalents$237.4M
Total debt$1.0M
Total equity$454.3M+421%
Total assets$467.8M

Cash flow

See full
Operating cash flow-$22.6M-47.6%
CapEx$23.0K
Free cash flow-$22.7M-47.8%

Valuation

See full
Market cap$2.32B+107%
Enterprise value$2.08B

Returns & leverage

See full
Return on equity-45.7%
Current ratio35.8×

Where this comes from

Calculated from Hemab Therapeutics Holdings, Inc.’s reported figures.

Based on the most recent quarter.

The source filing: Hemab Therapeutics Holdings, Inc.’s 10-Q, filed August 11, 2026. Open the filing →

Filed
Aug 11, 2026, 4:00 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-344533

FAQ

What is Hemab Therapeutics Holdings, Inc.'s debt-to-equity?
Hemab Therapeutics Holdings, Inc. (COAG) reported debt-to-equity of 0× in Q2 2026.
What does debt-to-equity mean?
Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.

Ask your AI about Hemab Therapeutics Holdings, Inc.'s debt-to-equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude